On 1 October 2025, the Indivior Board announced that it intends to pursue a change in domicile from the U.K. to the U.S. and will establish a new U.S. company—incorporated in Delaware and to be named Indivior Pharmaceuticals, Inc.—above its existing U.K. parent company. Indivior intends to implement the redomiciliation by means of a U.K. Court-sanctioned Scheme of Arrangement.
Effective January 26, 2026, Indivior Shareholders received Indivior Pharmaceuticals Shares in place of their Indivior Shares held on a one-for-one basis.
Indivior PLC became a wholly-owned subsidiary of Indivior Pharmaceuticals. The rights attaching to the Indivior Pharmaceuticals Shares are substantially the same to those attaching to the Indivior Shares including as to, and in respect of the same proportion of, the profits, net assets and dividends of the Group.
Important documents related to the proposed redomiciliation:
- Scheme Circular
- Post-Scheme Articles of Association for Indivior Limited, after re-registration as a LTD.
- Terms and conditions under which Computershare U.K. provides the Indivior Pharmaceuticals CSN
If you have any practical questions about the redomicile please call the Shareholder Helpline.
SHAREHOLDER HELPLINE TELEPHONE NUMBER:
Direct shareholders
TEL: 1 (866) 644-4127 (in the U.S.)
TEL: 1 (781) 575-2906 (outside the U.S.) (calls to this shareholder helpline from outside the U.S. are charged at the applicable international rates)
Indivior DI Holders and Indivior CSN Holders:
TEL: +44 (0) 370 707 1820(1) (calls to this helpline from outside the U.K. are charged at the applicable international rates)
Charges from mobiles and other operators may apply.